Chalasani Rohan, Krishnamurthy Sudarshan, Suda Katie J, Newman Terri V, Delaney Scott W, Essien Utibe R
Northwestern University.
Wake Forest University.
J Health Polit Policy Law. 2022 Dec 1;47(6):709-729. doi: 10.1215/03616878-10041135.
The United States pays more for medical care than any other nation in the world, including for prescription drugs. These costs are inequitably distributed, as individuals from underrepresented racial and ethnic groups in the United States experience the highest costs of care and unequal access to high-quality, evidence-based medication therapy. Pharmacoequity refers to equity in access to pharmacotherapies or ensuring that all patients, regardless of race and ethnicity, socioeconomic status, or availability of resources, have access to the highest quality of pharmacotherapy required to manage their health conditions. Herein the authors describe the urgent need to prioritize pharmacoequity. This goal will require a bold and innovative examination of social policy, research infrastructure, patient and prescriber characteristics, as well as health policy determinants of inequitable medication access. In this article, the authors describe these determinants, identify drivers of ongoing inequities in prescription drug access, and provide a framework for the path toward achieving pharmacoequity.
美国在医疗保健方面的支出比世界上任何其他国家都多，包括处方药。这些成本分配不均，因为在美国，代表性不足的种族和族裔群体的个人面临着最高的医疗成本，并且在获得高质量、循证药物治疗方面机会不平等。药物公平是指在获得药物治疗方面的公平，即确保所有患者，无论种族、族裔、社会经济地位或资源可得性如何，都能获得管理其健康状况所需的最高质量的药物治疗。在此，作者描述了将药物公平作为优先事项的迫切需求。这一目标将需要对社会政策、研究基础设施、患者和开处方者的特征以及药物获取不平等的卫生政策决定因素进行大胆而创新的审视。在本文中，作者描述了这些决定因素，确定了处方药获取方面持续存在不平等的驱动因素，并提供了实现药物公平之路的框架。
